ES2528797T3 - Compuestos de aza-benzotiofenilo y métodos de uso - Google Patents

Compuestos de aza-benzotiofenilo y métodos de uso Download PDF

Info

Publication number
ES2528797T3
ES2528797T3 ES07814268.4T ES07814268T ES2528797T3 ES 2528797 T3 ES2528797 T3 ES 2528797T3 ES 07814268 T ES07814268 T ES 07814268T ES 2528797 T3 ES2528797 T3 ES 2528797T3
Authority
ES
Spain
Prior art keywords
aza
methods
formula
benzothiophenyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07814268.4T
Other languages
English (en)
Spanish (es)
Inventor
Stephen Price
Karen Williams
Pascal Pierre Savy
Hazel Joan Dyke
John Gary Montana
Mark S. Stanley
Liang Bao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2528797(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2528797T3 publication Critical patent/ES2528797T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES07814268.4T 2006-08-21 2007-08-20 Compuestos de aza-benzotiofenilo y métodos de uso Active ES2528797T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US83916306P 2006-08-21 2006-08-21
US839163P 2006-08-21
US87160006P 2006-12-22 2006-12-22
US871600P 2006-12-22
US91762407P 2007-05-11 2007-05-11
US917624P 2007-05-11
PCT/US2007/076340 WO2008024724A1 (en) 2006-08-21 2007-08-20 Aza-benzothiophenyl compounds and methods of use

Publications (1)

Publication Number Publication Date
ES2528797T3 true ES2528797T3 (es) 2015-02-12

Family

ID=38800915

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07814268.4T Active ES2528797T3 (es) 2006-08-21 2007-08-20 Compuestos de aza-benzotiofenilo y métodos de uso

Country Status (16)

Country Link
US (1) US7893085B2 (index.php)
EP (1) EP2069359B1 (index.php)
JP (1) JP5349306B2 (index.php)
KR (1) KR101475088B1 (index.php)
AR (1) AR062469A1 (index.php)
AU (1) AU2007286807B2 (index.php)
BR (1) BRPI0714629A2 (index.php)
CA (1) CA2660963A1 (index.php)
CL (1) CL2007002431A1 (index.php)
ES (1) ES2528797T3 (index.php)
IL (1) IL197060A (index.php)
MX (1) MX2009001875A (index.php)
NO (1) NO20091198L (index.php)
PE (2) PE20120049A1 (index.php)
TW (1) TWI426078B (index.php)
WO (1) WO2008024724A1 (index.php)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660546A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
MX343368B (es) 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CA3018406A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CA3063535A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
PT3624796T (pt) 2017-05-19 2025-06-02 Nflection Therapeutics Inc Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
IL271230B2 (en) 2017-06-21 2024-06-01 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
MX2021000293A (es) 2018-07-09 2021-07-15 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos.
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
JP7406264B2 (ja) 2018-11-20 2023-12-27 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのシアノアリール－アニリン化合物
CA3120352A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
BR112021018631A2 (pt) 2019-03-19 2021-11-23 Boehringer Ingelheim Animal Health Usa Inc Compostos anti-helmínticos de aza-benzotiofeno e aza-benzofurano
CA3183100A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anthelmintic heterocyclic compounds
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
KR20240112282A (ko) 2021-11-01 2024-07-18 베링거잉겔하임베트메디카게엠베하 구충제 피롤로피리다진 화합물
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328920A (en) 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5214204A (en) 1991-07-19 1993-05-25 Abbott Laboratories Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity
US5403843A (en) 1991-08-12 1995-04-04 Takeda Chemical Industries, Ltd. Pyrrolopyrimidinyalglutaminate derivatives and their use
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4425609A1 (de) 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
BR9804865B1 (pt) 1997-04-24 2011-08-23 pesticida 3-(fenil substituìdo)-5-(tienil ou furil)-1,2,4-triazóis, composição para controlar insetos ou ácaros, bem como processo para controlar insetos, ácaros, moscas brancas e afìdios, para proteger plantas de afìdios, ácaros ou insetos.
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2777886B1 (fr) 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2181366T3 (es) 1998-06-30 2003-02-16 Lilly Co Eli Derivados de piperidina que tienen efectos sobre sistemas relacionados con serotonina.
CA2334897A1 (en) 1998-06-30 2000-01-06 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
JP2002519326A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するアゼピン誘導体
US6410562B1 (en) 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
EA200100772A1 (ru) * 1999-01-13 2002-02-28 Варнер-Ламберт Компани Бензогетероциклы и их применение в качестве мек ингибиторов
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
AP2001002217A0 (en) * 2000-07-19 2001-09-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
BR0307782A (pt) 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
SI2130537T1 (sl) * 2002-03-13 2013-01-31 Array Biopharma, Inc. N3-alkilirani derivati benzimidazola kot inhibitorji mek
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
DE60316829T2 (de) 2002-08-02 2008-07-10 Merck & Co., Inc. Substituierte furo[2,3-b]pyridin-derivate
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE10351436A1 (de) 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
JP2007514659A (ja) 2003-11-25 2007-06-07 イーライ リリー アンド カンパニー ペルオキシソーム増殖因子活性化受容体の修飾因子
WO2005058858A1 (en) 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
ATE455765T1 (de) 2003-12-22 2010-02-15 Basilea Pharmaceutica Ag Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
JP2008534664A (ja) * 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
BRPI0716224A2 (pt) 2006-08-31 2013-10-15 Array Biopharma Inc Compostos inibidores de raf e métodos de uso dos mesmos.

Also Published As

Publication number Publication date
CA2660963A1 (en) 2008-02-28
CL2007002431A1 (es) 2008-03-14
TWI426078B (zh) 2014-02-11
EP2069359B1 (en) 2014-11-12
IL197060A (en) 2014-12-31
MX2009001875A (es) 2009-03-02
PE20081359A1 (es) 2008-11-27
KR101475088B1 (ko) 2014-12-23
EP2069359A1 (en) 2009-06-17
KR20090047538A (ko) 2009-05-12
AR062469A1 (es) 2008-11-12
PE20120049A1 (es) 2012-02-16
US7893085B2 (en) 2011-02-22
IL197060A0 (en) 2009-11-18
TW200823222A (en) 2008-06-01
AU2007286807A1 (en) 2008-02-28
US20080081821A1 (en) 2008-04-03
BRPI0714629A2 (pt) 2013-05-07
WO2008024724A1 (en) 2008-02-28
AU2007286807B2 (en) 2013-03-21
JP2010501584A (ja) 2010-01-21
NO20091198L (no) 2009-05-20
JP5349306B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
ES2528797T3 (es) Compuestos de aza-benzotiofenilo y métodos de uso
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
PE20110424A1 (es) Isoindolonas que inhiben la cinasa mek
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20091158A1 (es) 5-anilinoimidazopiridinas y metodos de uso
CY1111671T1 (el) Ετεροκυκλικη ενωση
MA32075B1 (fr) Composes presentant une activite antagoniste de crth2
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
CO5611131A2 (es) Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
EA201170096A1 (ru) Замещенные производные пиримидона
AR058077A1 (es) Derivados de acidos fenoxiaceticos
DK1761520T3 (da) Kinaseinhibitorer
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
NI201000047A (es) Uso de 3, 11b-cis-dihidrotetrabenzina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria.
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
ES2485867T3 (es) Compuestos opioides de carboxamido
CO6290688A2 (es) Derivados de oxadiazol activos en 1-fosfato de esfingosina
ES2542615T3 (es) Sustratos para detección cromogénica y métodos de uso en los ensayos y kits de detección
ATE441645T1 (de) Neue antibiotische derivate
CO5700781A2 (es) Agonistas morfolinicos de la dopamina